Clinical Trials Logo

Clinical Trial Summary

Obstructive sleep apnea (OSA), a condition that affects a quarter of the Western adults, triples the risk for cardiovascular diseases and increases all-cause mortality. Intermittent hypoxia (IH) during transient cessation of breathing in OSA leads to endothelial inflammation, a key step in the initiation and progression of cardiovascular disease. However, the mechanisms that mediate IH-induced endothelial inflammation remain unclear and, consequently, no targeted therapy is available for vascular manifestations of OSA. Using endothelial cells (ECs) freshly harvested from OSA patients, they study team has identified impaired complement inhibition as an initial stimulus for endothelial inflammation in IH, thereby linking for the first time complement activation to vascular risk in OSA. The investigators found that a major complement inhibitor cluster of differentiation (CD59), a plasma membrane protein that inhibits the formation of the terminal complement membrane attack complex (MAC) and protects host cells from complement injury, is internalized from the EC surface in OSA patients. Consequent MAC deposition initiates endothelial inflammation in IH. Importantly, the investigators showed that IH does not significantly affect inflammation in ECs in the absence of complement, suggesting that complement activation has an essential role in endothelial inflammation in OSA. Interestingly, internalization of CD59 in IH appears to be cholesterol-dependent and statins prevent MAC deposition on ECs in IH in a CD59-dependent manner, suggesting a novel therapeutic strategy to reduce vascular risk in OSA. This led the study team to hypothesize that IH-induced cellular cholesterol accumulation reduces complement inhibition via increased internalization of CD59 from the EC surface leading to increased MAC deposition, and that treatment of OSA with continuous positive airway pressure (CPAP) and/or statins reverses endothelial dysfunction by restoring complement inhibition.


Clinical Trial Description

To address the hypothesis, the investigators seek to determine whether statins prevent endothelial dysfunction in OSA by restoring complement inhibition. The preliminary data indicate that the expression of CD59 on the EC surface is preserved in OSA patients who are receiving statins and that statins prevent CD59 internalization and MAC deposition in IH leading to reduced inflammation. The study proposes to determine whether statins restore endothelial protection against complement activity in OSA patients using double-blind placebo-controlled parallel group randomized study design. The hypothesis: The proportion of CD59 on the EC surface is increased while MAC deposition is decreased after 4 weeks of atorvastatin 10 mg daily compared with placebo in OSA patients who adhere with CPAP or do not adhere with CPAP. The proposed studies may advance our understanding of vascular dysfunction in OSA and provide the basis for large, long-term clinical trials of novel therapeutic strategies, such as addition of statins to the standard CPAP therapy, for preventing and/or reversing vascular risk in OSA. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03122639
Study type Interventional
Source Columbia University
Contact
Status Completed
Phase Early Phase 1
Start date September 1, 2017
Completion date May 7, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05489562 - Use of Intraoral Suction and Its Effects on Obstructive Sleep Apnea N/A
Recruiting NCT05717959 - Efficacy of Oropharyngeal Exercises for Patients With Obstructive Sleep Apnea Using Mandibular Advancement Device N/A
Recruiting NCT06008626 - Clinical Trial of the Cryosa System for the Treatment of Obstructive Sleep Apnea N/A
Completed NCT03940781 - Effects of Rehabilitation for Patients With Obstructive Sleep Apnea N/A
Recruiting NCT05289063 - Vascular Endothelial Dysfunction in Sleep Apnea Phase 1
Not yet recruiting NCT05268471 - Cost-effectiveness Analysis and Conditional Response to the Effect of Positional Devices in Obstructive Sleep Apnea N/A
Active, not recruiting NCT04864652 - Safety and Dosing Study of the CHILLS Cryotherapy for the Treatment of OSA N/A
Enrolling by invitation NCT05433883 - The Relationship Between Obstructive Sleep Apnea and Alzheimer's Disease: Evidence and Effectiveness N/A
Recruiting NCT06103630 - Efficacy of Oropharyngeal Exercises for Patients With Obstructive Sleep Apnea Using Mandibular Advancement Device N/A
Recruiting NCT06283095 - Management of Obstructive Sleep Apnea Syndrome by Expansion Palatoplasty N/A
Completed NCT03156283 - SleepWell24: An Innovative Smartphone Application to Improve PAP Adherence N/A
Completed NCT03362385 - OSA-ACS Project: Association of OSA and CPAP Therapy With Outcomes in ACS Patients
Recruiting NCT06447818 - Changes in Difficult Airway Markers After Surgery for Obstructive Sleep Apnoea Syndrome
Completed NCT04643782 - Comparative Study of the ANNEā„¢ One System to Diagnose Obstructive Sleep Apnea N/A
Recruiting NCT03463785 - Does Race Make a Difference in Obstructive Sleep Apnea?
Recruiting NCT03618719 - Impact of Intermittent Hypoxia on the Function of the Phagocytes
Completed NCT03048604 - BiLAteral Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnoea (BLAST OSA) N/A
Recruiting NCT05290350 - Long COVID-19 Fatigue and Obstructive Sleep Apnea
Recruiting NCT05739617 - Comprehensive Respiratory Training Exercise Program in Obstructive Sleep Apnea N/A
Completed NCT03980158 - Change in Tongue Strength and Fatigue After Upper Airway Stimulation Therapy